Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate

NCT01692652 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)

Interventions

DRUG: topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage
OTHER: warm compress only group

Sponsor

Yonsei University